Additional challenges to complete, accurate diagnoses in the FTD-ALS spectrum include a lack of TDP-43 biomarkers and often rapid progression which may preclude evaluation of the full clinical picture. Here, TARDBP is linked to amyotrophic lateral sclerosis.